DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -85.24 Million EUR | 11.78% |
| 2022 | -96.63 Million USD | 2.01% |
| 2021 | -98.61 Million USD | 37.92% |
| 2020 | -158.84 Million EUR | 6.53% |
| 2019 | -169.93 Million EUR | 10.62% |
| 2018 | -190.11 Million EUR | -9.3% |
| 2017 | -173.93 Million EUR | -42.54% |
| 2016 | -122.02 Million EUR | -145.06% |
| 2015 | -49.79 Million EUR | -66.22% |
| 2014 | -29.95 Million EUR | -8.73% |
| 2013 | -27.55 Million EUR | -54.27% |
| 2012 | -17.85 Million EUR | -89.78% |
| 2011 | -9.41 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -28.55 Million USD | -139.58% |
| 2024 Q2 | -33.84 Million USD | -18.5% |
| 2023 Q1 | -21.16 Million USD | 44.33% |
| 2023 FY | -85.24 Million EUR | 11.78% |
| 2023 Q4 | -11.92 Million USD | 34.86% |
| 2023 Q3 | -18.3 Million USD | 27.02% |
| 2023 Q2 | -25.07 Million USD | -18.48% |
| 2022 Q3 | -18.02 Million USD | 24.36% |
| 2022 Q4 | -38.01 Million USD | -110.97% |
| 2022 Q1 | -16.77 Million USD | -24.44% |
| 2022 Q2 | -23.82 Million USD | -42.05% |
| 2022 FY | -96.63 Million USD | 2.01% |
| 2021 Q1 | -29.63 Million USD | 26.21% |
| 2021 Q2 | -31.13 Million USD | -5.06% |
| 2021 Q3 | -24.36 Million USD | 21.73% |
| 2021 Q4 | -13.47 Million USD | 44.69% |
| 2021 FY | -98.61 Million USD | 37.92% |
| 2020 Q1 | -41.22 Million USD | 15.29% |
| 2020 Q3 | -29.76 Million USD | 37.59% |
| 2020 FY | -158.84 Million EUR | 6.53% |
| 2020 Q4 | -40.16 Million USD | -34.93% |
| 2020 Q2 | -47.69 Million USD | -15.7% |
| 2019 FY | -169.93 Million EUR | 10.62% |
| 2019 Q4 | -48.66 Million EUR | -56.63% |
| 2019 Q1 | -44.49 Million USD | 16.98% |
| 2019 Q2 | -45.1 Million USD | -1.38% |
| 2019 Q3 | -31.07 Million EUR | 31.11% |
| 2018 FY | -190.11 Million EUR | -9.3% |
| 2018 Q4 | -53.59 Million EUR | -4.02% |
| 2018 Q3 | -51.51 Million EUR | -20.01% |
| 2018 Q2 | -42.92 Million USD | 5.21% |
| 2018 Q1 | -45.28 Million USD | -2.17% |
| 2017 Q2 | -40.61 Million USD | -7.06% |
| 2017 Q3 | -43.66 Million USD | -7.52% |
| 2017 Q4 | -44.32 Million USD | -1.51% |
| 2017 FY | -173.93 Million EUR | -42.54% |
| 2017 Q1 | -37.93 Million USD | -8.12% |
| 2016 Q1 | -28.11 Million USD | -68.99% |
| 2016 FY | -122.02 Million EUR | -145.06% |
| 2016 Q4 | -35.08 Million USD | 6.3% |
| 2016 Q3 | -37.44 Million USD | -36.57% |
| 2016 Q2 | -27.41 Million USD | 2.49% |
| 2015 Q1 | -6.9 Million USD | 9.33% |
| 2015 FY | -49.79 Million EUR | -66.22% |
| 2015 Q4 | -16.63 Million USD | 2.68% |
| 2015 Q3 | -17.09 Million USD | -80.78% |
| 2015 Q2 | -9.45 Million USD | -36.97% |
| 2014 Q4 | -7.61 Million USD | 3.91% |
| 2014 FY | -29.95 Million EUR | -8.73% |
| 2014 Q1 | -7.35 Million USD | 8.62% |
| 2014 Q2 | -9.22 Million USD | -25.32% |
| 2014 Q3 | -7.92 Million USD | 14.07% |
| 2013 Q2 | -5.36 Million USD | -1.46% |
| 2013 Q3 | -7.91 Million USD | -47.48% |
| 2013 Q4 | -8.05 Million USD | -1.74% |
| 2013 FY | -27.55 Million EUR | -54.27% |
| 2013 Q1 | -5.28 Million USD | -3.21% |
| 2012 Q3 | -4.99 Million USD | 0.0% |
| 2012 FY | -17.85 Million EUR | -89.78% |
| 2012 Q4 | -5.12 Million USD | -2.66% |
| 2011 FY | -9.41 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -2398.423% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 33.075% |
| Adocia SA | -17.62 Million EUR | -383.749% |
| Aelis Farma SA | -6.46 Million EUR | -1219.396% |
| Biophytis S.A. | -14.33 Million EUR | -494.755% |
| Advicenne S.A. | -6.45 Million EUR | -1220.214% |
| genOway Société anonyme | 2.06 Million EUR | 4227.554% |
| IntegraGen SA | -183.77 Thousand EUR | -46287.441% |
| Medesis Pharma S.A. | -4.22 Million EUR | -1915.591% |
| Neovacs S.A. | -6.9 Million EUR | -1134.102% |
| NFL Biosciences SA | -4.43 Million EUR | -1824.111% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -10853.758% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -2617.223% |
| Sensorion SA | -22.31 Million EUR | -282.088% |
| Theranexus Société Anonyme | -7.64 Million EUR | -1015.251% |
| TME Pharma N.V. | -5.62 Million EUR | -1415.757% |
| Valbiotis SA | -7.16 Million EUR | -1090.589% |
| TheraVet SA | -2.17 Million EUR | -3819.169% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -320.18% |
| argenx SE | -417.15 Million EUR | 79.565% |
| BioSenic S.A. | -7.04 Million EUR | -1110.884% |
| Celyad Oncology SA | -8.45 Million EUR | -907.996% |
| Galapagos NV | -88.26 Million EUR | 3.418% |
| Genfit S.A. | -26.58 Million EUR | -220.716% |
| GeNeuro SA | -14.35 Million EUR | -493.748% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -433.022% |
| Innate Pharma S.A. | -12.66 Million EUR | -572.872% |
| Inventiva S.A. | -102.7 Million EUR | 17.002% |
| MaaT Pharma SA | -19.94 Million EUR | -327.449% |
| MedinCell S.A. | -20.97 Million EUR | -306.379% |
| Nanobiotix S.A. | -26.77 Million EUR | -218.332% |
| Onward Medical N.V. | -35.46 Million EUR | -140.381% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -1773.875% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -270.861% |
| Oxurion NV | -12.11 Million EUR | -603.932% |
| Pharming Group N.V. | -4.87 Million EUR | -1647.012% |
| Poxel S.A. | -28.76 Million EUR | -196.364% |
| GenSight Biologics S.A. | -29.69 Million EUR | -187.063% |
| Transgene SA | -30.01 Million EUR | -184.04% |
| Financière de Tubize SA | -2.14 Million EUR | -3876.084% |
| UCB SA | 604 Million EUR | 114.114% |
| Valneva SE | -82.08 Million EUR | -3.849% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -195.614% |